FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W181063178> ?p ?o ?g. }

• W181063178 endingPage "471" @default.
• W181063178 startingPage "470" @default.
• W181063178 abstract "Dear Sir,We read with interest the letter by Marietta and colleagues1 and agree that we should be looking at clinical instead of surrogate endpoints, such as the INR, when comparing the efficacy of 3 and 4 factor PCCs for warfarin reversal. The ideal trial to give this answer will be a large randomised double blind trial of 3 vs 4 factor PCC in patients on the same anticoagulant and where the dose, timing and route of intravenous vitamin K co-administration is the same, the PCC dose is the same and where randomisation is grouped according to INR, indication for anticoagulation and type of bleeding. Such a trial, however, is unlikely to ever be done.In the absence of such a trial we are left with studies which vary enormously and where comparisons are fraught with danger. Because of the wide variability in patient factors and the way and timing that treatments are given, it is not easy to compare studies. As an alternative we would like the reader to consider the patient with an INR of 15.0 and a cerebral bleed. The patient is likely to have levels of factors II, VII, IX and X of 50%. It is unlikely that clinicians with expertise in managing patients with inherited FVII deficiency will be happy not to try and improve the FVII level of such a patient.An axrgument for the safety and effectiveness of 3 factor PCCs despite incomplete correction of the INR is that it is the prothrombin fraction in PCC that is responsible for the correction of the bleeding tendency and that the FVII fraction is less important2. The importance of prothrombin is shown by both in vitro3 and ex vivo4 experiments using thrombin generation showing a linear relationship between prothrombin and thrombin generation, whereas FVII has a hyperbolic relationship reaching normal thrombin generation at levels of around 5%. The prothrombin concentration after treatment with 3 factor PCC in the study by Holland et al. increased from 0.05 u/mL to 0.53 u/mL5. The latter is only at the lower limit of normal and given the linear relationship with thrombin generation, it is unlikely to fully compensate for the reduced levels of FVII (0.10 u/mL after treatment) that potentially continue to confer a bleeding risk.Marietta and colleagues correctly raise the issue of safety of PCCs and suggest a reduced thrombotic tendency with 3 factor products based on the abstract by Dentali et al6. This meta-analysis showed a thrombotic incidence for 4 factor PCC of 2.3% versus 0.7% for 3 factor products but the 95% confidence intervals overlap (1.2–3.8% vs 0.0–2.4%) and the difference is not significant.Whilst we agree with Marietta and colleagues1 that we should concentrate on improving the use of PCC in patients with major bleeding in the context of coumarin anticoagulation, we remain convinced that for patients with very high INRs and truly life-threatening bleeding the 3 and 4 factor PCCs cannot be considered to be of equal efficacy at present. An approach whilst waiting for the evidence that 3 factor PCCs are clinically efficacious in patients with very high INRs is to also administer a small volume of fresh frozen plasma7." @default.
• W181063178 created "2016-06-24" @default.
• W181063178 creator A5034546647 @default.
• W181063178 creator A5052873285 @default.
• W181063178 date "2011-10-01" @default.
• W181063178 modified "2023-09-25" @default.
• W181063178 title "Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? The true question is: what are we looking for?" @default.
• W181063178 doi "https://doi.org/10.2450/2011.0045-11" @default.
• W181063178 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3200420" @default.
• W181063178 hasPublicationYear "2011" @default.
• W181063178 type Work @default.
• W181063178 sameAs 181063178 @default.
• W181063178 citedByCount "1" @default.
• W181063178 countsByYear W1810631782014 @default.
• W181063178 crossrefType "journal-article" @default.
• W181063178 hasAuthorship W181063178A5034546647 @default.
• W181063178 hasAuthorship W181063178A5052873285 @default.
• W181063178 hasConcept C126322002 @default.
• W181063178 hasConcept C141071460 @default.
• W181063178 hasConcept C141341695 @default.
• W181063178 hasConcept C187212893 @default.
• W181063178 hasConcept C2776259030 @default.
• W181063178 hasConcept C2776301958 @default.
• W181063178 hasConcept C2777091921 @default.
• W181063178 hasConcept C2778382381 @default.
• W181063178 hasConcept C2779161974 @default.
• W181063178 hasConcept C2780930249 @default.
• W181063178 hasConcept C2781221834 @default.
• W181063178 hasConcept C2909974469 @default.
• W181063178 hasConcept C2993590494 @default.
• W181063178 hasConcept C535046627 @default.
• W181063178 hasConcept C71924100 @default.
• W181063178 hasConceptScore W181063178C126322002 @default.
• W181063178 hasConceptScore W181063178C141071460 @default.
• W181063178 hasConceptScore W181063178C141341695 @default.
• W181063178 hasConceptScore W181063178C187212893 @default.
• W181063178 hasConceptScore W181063178C2776259030 @default.
• W181063178 hasConceptScore W181063178C2776301958 @default.
• W181063178 hasConceptScore W181063178C2777091921 @default.
• W181063178 hasConceptScore W181063178C2778382381 @default.
• W181063178 hasConceptScore W181063178C2779161974 @default.
• W181063178 hasConceptScore W181063178C2780930249 @default.
• W181063178 hasConceptScore W181063178C2781221834 @default.
• W181063178 hasConceptScore W181063178C2909974469 @default.
• W181063178 hasConceptScore W181063178C2993590494 @default.
• W181063178 hasConceptScore W181063178C535046627 @default.
• W181063178 hasConceptScore W181063178C71924100 @default.
• W181063178 hasIssue "4" @default.
• W181063178 hasLocation W1810631781 @default.
• W181063178 hasOpenAccess W181063178 @default.
• W181063178 hasPrimaryLocation W1810631781 @default.
• W181063178 hasRelatedWork W1650664790 @default.
• W181063178 hasRelatedWork W1804461895 @default.
• W181063178 hasRelatedWork W1966427644 @default.
• W181063178 hasRelatedWork W1980040441 @default.
• W181063178 hasRelatedWork W1988502808 @default.
• W181063178 hasRelatedWork W2012867575 @default.
• W181063178 hasRelatedWork W2026018991 @default.
• W181063178 hasRelatedWork W2080900919 @default.
• W181063178 hasRelatedWork W2084860110 @default.
• W181063178 hasRelatedWork W2087918910 @default.
• W181063178 hasRelatedWork W2103189326 @default.
• W181063178 hasRelatedWork W2115186148 @default.
• W181063178 hasRelatedWork W2121371632 @default.
• W181063178 hasRelatedWork W2144340867 @default.
• W181063178 hasRelatedWork W223940108 @default.
• W181063178 hasRelatedWork W2890228929 @default.
• W181063178 hasRelatedWork W788640443 @default.
• W181063178 hasRelatedWork W89122497 @default.
• W181063178 hasRelatedWork W2313011189 @default.
• W181063178 hasRelatedWork W2740642219 @default.
• W181063178 hasVolume "9" @default.
• W181063178 isParatext "false" @default.
• W181063178 isRetracted "false" @default.
• W181063178 magId "181063178" @default.
• W181063178 workType "article" @default.